Partnership Aims to Accelerate Innovation in Diagnostic Tools for Patients with Complex Tick and Vector-Borne Illnesses DURHAM, N.C., June 2nd, 2026, Galaxy Diagnostics, a leader in advanced vector-borne disease testing, has announced a strategic investment from Bay Area Lyme Ventures, the newly launched impact investment fund created by Bay Area Lyme Foundation to accelerate innovation… Continue reading Bay Area Lyme Ventures Invests in Galaxy Diagnostics to Advance Tick-Borne Disease Testing
By Jennifer C. Miller, PhD, Vice President of Clinical & Scientific Operations, Galaxy Diagnostics Summary: Babesia is an intraerythrocytic parasite that has become one of the most persistent diagnostic blind spots in tick-borne medicine. Despite growing clinical recognition, standard testing methods frequently fail to detect Babesia in chronic presentations, where parasitemia is low, symptoms… Continue reading The Babesia Detection Problem: Why Results Differ in Low-Level Parasitemia
Babesia is often present but rarely detected. In this clinical webinar, learn why standard diagnostics fall short, how pathogen biology creates testing gaps, and how to interpret discordant results with confidence.
When Bartonella infections persist, present atypically, or defy standard testing, understanding why they are missed is critical. This webinar examines Bartonella’s stealth biology, non-traditional transmission routes, and diagnostic blind spots through clinically grounded case studies, providing actionable insight for providers navigating complex vector-borne disease presentations.
By Edward B. Breitschwerdt, DVM, Co-Founder, Galaxy Diagnostics, and Distinguished Professor Emeritus of Internal Medicine and Infectious Diseases, NC State University College of Veterinary Medicine Summary: Bartonella is one of the most diagnostically overlooked pathogens in clinical medicine, not because it is rare, but because the standard tools used to find it (including both… Continue reading Bartonella: The Blind Spot Pathogen Clinicians Can’t Afford to Miss
Galaxy Diagnostics and Virginia Tech Unite to Advance Testing for Lyme Disease By Nicole Danielle Bell, CEO of Galaxy Diagnostics and author of What Lurks in the Woods When a Test Fails a Patient When diagnostics fail patients, the consequences are real. I’ve lived it. My husband tested negative using the current standard-of-care test for… Continue reading Two LymeX Innovators, One Mission: Better Answers for Patients
